Literature DB >> 17327954

Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.

R Yoshimura1, K Shinkai, N Ueda, J Nakamura.   

Abstract

OBJECTIVE: To investigate the effect of valproic acid on plasma levels of risperidone and its active metabolite, 9-hydroxyrisperidone under steady state conditions in 12 schizophrenic patients.
METHODS: The efficacy and tolerability for the combination treatment of valproic acid and risperidone were examined.
RESULTS: The addition of valproic acid to risperidone significantly reduced total scores of PANSS positive symptoms, especially excitement and hostility scores, but did not change SAS scores. Addition of valproic acid did not alter plasma concentrations of risperidone or 9-hydroxyrisperidone or active moiety, and the risperidone/9-hydroxyrisperidone ratio. The combination of valproic acid with risperidone decreased plasma levels of HVA, but not those of MHPG; additionally, treatment with this combination was found to reduce dopaminergic activity.
CONCLUSION: These results suggest that the addition of valproic acid to risperidone is both effective and well tolerated for treating excitement and impulsiveness in schizophrenic patients without influencing the metabolism of risperidone, and treatment with valproic acid and risperidone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327954     DOI: 10.1055/s-2007-958521

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

Review 1.  Diet and the epigenetic (re)programming of phenotypic differences in behavior.

Authors:  Patrick O McGowan; Michael J Meaney; Moshe Szyf
Journal:  Brain Res       Date:  2008-07-29       Impact factor: 3.252

2.  Priapism associated with risperidone: a case report, literature review and review of the South London and Maudsley hospital patients' database.

Authors:  Lise Paklet; Anne Mary Abe; Dele Olajide
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

3.  Paliperidone: the evidence of its therapeutic value in schizophrenia.

Authors:  Joshua Kantrowitz; Leslie Citrome
Journal:  Core Evid       Date:  2008-07-31

4.  Functional hallucinations in schizophrenia responding to adjunctive sodium valproate.

Authors:  Ravi Philip Rajkumar
Journal:  Indian J Psychol Med       Date:  2012-01

Review 5.  Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study.

Authors:  Ping-Tao Tseng; Yen-Wen Chen; Weilun Chung; Kun-Yu Tu; Hung-Yu Wang; Ching-Kuan Wu; Pao-Yen Lin
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.